Where does Norm Coleman stand on Medicare Part D?
He voted for it. While the legislation has brought financial hardship to thousands of seniors in need of prescription, it has been a win for pharmaceuticals. Dr. Timothy Anderson, a pharmaceutical analyst with the Prudential Equity Group, estimated that under Medicare Part D, revenue to Glaxo from sale of the drug Lamcital would increase by $298 million in 2007, AstraZeneca’s sales of Seroquel would increase by $521 million, and Plavix revenue would increase by $169 million (Source: Milt Freudenheim, New York Times, July 18, 2006). Coincidentally, according to the Center for Responsive Politics, as of July 28, 2008, Coleman had received contributions totalling $206,317 from the pharmaceutical / health products industry during the current election cycle. Senator Coleman did go on record as voting for a measure that would limit debate and bring to the floor a bill that would have allowed Medicare to negotiate drug prices in 2007. However, the measure was never expected to pass, failing b
